Background: The results of analytical studies show that the association between hypertension and the risk of Parkinson’s disease (PD) remains controversial. Method: We searched studies related to the association between hypertension and the risk of PD. We pooled the ORs and risk ratios (RRs) with 95% confidence interval (CI) with random effects model and conducted meta-regression to explore potential sources of heterogeneity. Publication bias was estimated by Egger’s test and the funnel plot. Results: Twenty-six articles containing 27 studies were included, involving 9 cohort studies and 18 case-control studies. In cohort studies, compared with the non-hypertension participants, the pooled RR for the risk of PD was 1.70 (95% CI 1.60–1.80) for the patients with hypertension. In case-control studies, compared with the non-hypertension participants, the pooled OR for the risk of PD was 0.85 (95% CI 0.78–0.92) for the patients with hypertension. There were no publication bias in cohort studies and case-control studies. Conclusion: Based on population-based cohort studies, this meta-analysis indicated that hypertension might increase the risk of PD. In view of both hypertension and PD having an association with aging, case-control studies, especially the studies based on hospital records, were not suitable for similar studies.

Keywords:
Hypertension, Parkinson’s disease, Meta-analysis
1.
Zheng KS, Dorfman BJ, Christos PJ, Khadem NR, Henchcliffe C, Piboolnurak P, Nirenberg MJ: Clinical characteristics of exacerbations in Parkinson disease. Neurologist 2012; 18: 120–124.
2.
de Lau LM, Breteler MM: Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5: 525–535.
3.
Pringsheim T, Jette N, Frolkis A, Steeves TD: The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014; 29: 1583–1590.
4.
Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J: Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011; 26(suppl 1):S1–S58.
5.
Liu R, Guo X, Park Y, Wang J, Huang X, Hollenbeck A, Blair A, Chen H: Alcohol consumption, types of alcohol, and Parkinson’s disease. PLoS One 2013; 8:e66452.
6.
Zhang D, Jiang H, Xie J: Alcohol intake and risk of Parkinson’s disease: a meta-analysis of observational studies. Mov Disord 2014; 29: 819–822.
7.
Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ: A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 2002; 52: 276–284.
8.
Etminan M, Gill SS, Samii A: Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 2005; 4: 362–365.
9.
Gagne JJ, Power MC: Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74: 995–1002.
10.
Li AA, Mink PJ, McIntosh LJ, Teta MJ, Finley B: Evaluation of epidemiologic and animal data associating pesticides with Parkinson’s disease. J Occup Environ Med 2005; 47: 1059–1087.
11.
Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S: A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology 2000; 21: 435–440.
12.
Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS: Environmental risk factors and Parkinson’s disease: a metaanalysis. Environ Res 2001; 86: 122–127.
13.
Jiang W, Ju C, Jiang H, Zhang D: Dairy foods intake and risk of Parkinson’s disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol 2014; 29: 613–619.
14.
Ascherio A, Tanner CM: Use of antihypertensives and the risk of Parkinson disease. Neurology 2009; 72: 578–579.
15.
Powers KM, Smith-Weller T, Franklin GA, Longstreth WT Jr, Swanson PD, Checkoway H: Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord 2006; 12: 185–189.
16.
Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M; Fukuoka Kinki Parkinson’s Disease Study Group: Case-control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 2010; 293: 82–86.
17.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.
18.
Faraco G, Iadecola C: Hypertension: a harbinger of stroke and dementia. Hypertension 2013; 62: 810–817.
19.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the joint National committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–1252.
20.
Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM: Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009; 8: 165–174.
21.
Paganini-Hill A: Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology 2001; 20: 118–124.
22.
Herishanu YO, Medvedovski M, Goldsmith JR, Kordysh E: A case-control study of Parkinson’s disease in urban population of southern Israel. Can J Neurol Sci 2001; 28: 144–147.
23.
Chen CY, Hung HJ, Chang KH, Hsu CY, Muo CH, Tsai CH, Wu TN: Long-term exposure to air pollution and the incidence of Parkinson’s disease: a nested case-control study. PLoS One 2017; 12:e0182834.
24.
Das SK, Misra AK, Ray BK, Hazra A, Ghosal MK, Chaudhuri A, Roy T, Banerjee TK, Raut DK: Epidemiology of Parkinson disease in the city of Kolkata, India: a community-based study. Neurology 2010; 75: 1362–1369.
25.
Friedman B, Lahad A, Dresner Y, Vinker S: Long-term statin use and the risk of Parkinson’s disease. Am J Manag Care 2013; 19: 626–632.
26.
Qiu C, Hu G, Kivipelto M, Laatikainen T, Antikainen R, Fratiglioni L, Jousilahti P, Tuomilehto J: Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK study. Hypertension 2011; 57: 1094–1100.
27.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
28.
Higgins JP, Thompson SG: Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663–1682.
29.
Tobias A: Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999; 8: 7526–7529.
30.
Patsopoulos NA, Evangelou E, Ioannidis JP: Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008; 37: 1148–1157.
31.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
32.
Rajput AH, Offord KP, Beard CM, Kurland LT: A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 1987; 37: 226–232.
33.
Ho SC, Woo J, Lee CM: Epidemiologic study of Parkinson’s disease in Hong Kong. Neurology 1989; 39: 1314–1318.
34.
Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA: Risk-factors for Parkinson’s disease: case-control study in the province of caceres, Spain. Acta Neurol Scand 1994; 89: 164–170.
35.
McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, McManus ME, Pond SM: The epidemiology of Parkinson’s disease in an Australian population. Neuroepidemiology 1998; 17: 310–317.
36.
Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F: Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006; 37: 1184–1188.
37.
Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, Chiu DT: Increased oxidative damage in peripheral blood correlates with severity of Parkinson’s disease. Neurobiol Dis 2009; 33: 429–435.
38.
Cereda E, Cassani E, Barichella M, Spadafranca A, Caccialanza R, Bertoli S, Battezzati A, Pezzoli G: Low cardiometabolic risk in Parkinson’s disease is independent of nutritional status, body composition and fat distribution. Clin Nutr 2012; 31: 699–704.
39.
Savica R, Grossardt BR, Ahlskog JE, Rocca WA: Metabolic markers or conditions preceding Parkinson’s disease: a case-control study. Mov Disord 2012; 27: 974–979.
40.
Miao G: A Case-Control Study on the Risk of Hypertension, Hyperuricemia, Lifestyle and Parkinson’s Disease. Suzhou, Soochow University, 2015, pp 1–36.
41.
Pinzon R: Is hypertension and certain anti hypertensive agents increase the risk of Parkinson disease? J Hypertens 2017; 35.
42.
Grandinetti A, Morens DM, Reed D, MacEachern D: Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol 1994; 139: 1129–1138.
43.
Simon KC, Chen H, Schwarzschild M, Ascherio A: Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688–1695.
44.
Lai SW, Liao KF, Lin CL, Lin CC, Sung FC: Hearing loss may be a non-motor -feature of Parkinson’s disease in older people in Taiwan. Eur J Neurol 2014; 21: 752–757.
45.
Lai SW, Lin CL, Liao KF, Chang-Ou KC: Increased risk of Parkinson’s disease in cataract patients: a population-based cohort study. Parkinsonism Relat Disord 2015; 21: 68–71.
46.
Saaksjarvi K, Knekt P, Mannisto S, Lyytinen J, Heliovaara M: Prospective study on the components of metabolic syndrome and the incidence of Parkinson’s disease. Parkinsonism Relat Disord 2015; 21: 1148–1155.
47.
Hsu YC, Chang CW, Lee HL, Chuang CC, Chiu HC, Li WY, Horng JT, Fu E: Association between history of dental amalgam fillings and risk of Parkinson’s disease: a population-based retrospective cohort study in Taiwan. PLoS One 2016; 11: e0166552.
48.
Pupillo E, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, Lapi F, Beghi E: Epidemiology of Parkinson’s disease: a population-based study in primary care in Italy. Neuroepidemiology 2016; 47: 38–45.
49.
Hou L, Li Q, Jiang L, Qiu H, Geng C, Hong JS, Li H, Wang Q: Hypertension and diagnosis of Parkinson’s disease: a meta-analysis of cohort studies. Front Neurol 2018; 9: 162.
50.
Lash TL, Rothman K, Greenland: Modern Epidemiology 3rd 2008. Lippincott, Williams, and Wilkins.
51.
Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS: Antihypertensive agents and risk of Parkinson’s disease: a nationwide cohort study. PLoS One 2014; 9:e98961.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.